All In Biotech

NDA 021129 · Viatris

Neurontin

Gabapentin · Oral

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Mar 2, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

501

111 Phase 3, 25 recruiting

FAERS reports

364,199

231,729 serious, 34,539 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2026.

NEURONTIN ® is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )

Mechanism: The precise mechanisms by which gabapentin produces its analgesic and antiepileptic actions are unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. In vitro studies have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NEURONTIN · GABAPENTIN 250MG/5ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Gabapentin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective29,887
  • fatigue25,265
  • nausea23,025
  • pain21,365
  • off label use20,051
  • diarrhoea18,346
  • headache18,088
  • dizziness16,383
  • fall15,680
  • dyspnoea14,449
  • vomiting12,290
  • asthenia12,066

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,727
20054,880
20064,578
20073,890
20083,697
20094,759
20107,706
20117,641
201210,961
201311,532
201414,043
201521,637
201625,871
201725,518
201830,289
201931,872
202027,335
202123,435
202222,063
202321,333
202420,663
202521,482
202615,281

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Neurontin (Gabapentin)

2024 spending

$18.6M

Beneficiaries

2,346

11,760 claims

Per beneficiary

$7,911

$8.88 per unit

View as table
YearSpending
2020$25,573,642
2021$21,876,338
2022$20,550,126
2023$20,190,369
2024$18,559,673

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,415 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.